Data · dataset · 2026
<p>Mutation patterns and survival according to response to Aza/Ven.</p>
Listed in UCL Research Data Repository
<p>A. Concordance between G-banding and ELN 2022 cytogenetic risk classifications.
Description
Sankey diagram showing reclassification of patients (n = 53) from conventional G-banding–based cytogenetic risk groups (left) to ELN 2022 risk groups (right). Flow width is proportional to the number of cases.
Of 1 patient classified as favorable by G-banding, 1 remained favorable under ELN 2022. Of 30 patients classified as intermediate, 16 remained intermediate, 5 were reclassified as favorable, and 9 were reclassified as adverse. Genes involved in risk reclassification included <i>NPM1</i> for intermediate-to-favorable reclassification (n = 5), and <i>EZH2</i> (n = 2), <i>RUNX1</i> (n = 2), <i>SRSF2</i> (n = 2), <i>TP53</i> (n = 2), and <i>U2AF1</i> (n = 1) for intermediate-to-adverse reclassification.
Read the rest (4 more)
All 22 patients classified as adverse remained adverse under ELN 2022, resulting in 31 adverse cases in total. B. Overall survival according to response to first-line Aza/Ven. C. Treatment response according to gene mutation (n ≥ 2).
CR/CRi ratios were as follows: <i>IDH1</i> (100%, n = 3), <i>IDH2</i> (100%, n = 3), <i>FLT3-TKD</i> (83%, n = 6), <i>PTPN11</i> (80%, n = 5), <i>NRAS</i> (71%, n = 7), <i>CBL</i> (67%, n = 3), <i>FLT3-ITD</i> (63%, n = 8), <i>NPM1</i> (62%, n = 13), <i>SRSF2</i> (50%, n = 4), <i>EZH2</i> (50%, n = 2), <i>SETBP1</i> (50%, n = 2), <i>NF1</i> (50%, n = 4), <i>GATA2</i> (50%, n = 2), <i>TP53</i> (42%, n = 12), <i>RUNX1</i> (25%, n = 4), and <i>KRAS</i> (17%, n = 6).
Green indicates Type 1 mutations, purple indicates Type 2 mutations, and blue indicates other mutations. D. Distribution of treatment response (CR/CRi vs non-CR). CR/CRi (n = 52): type 1 (63%, n = 33), type 2 (15%, n = 8), others (21%, n = 11).
Non-CR (n = 38): type 1 (32%, n = 12), type 2 (42%, n = 16), others (26%, n = 10) (p = 0.0050). Aza, azacitidine; CR, complete remission; CRi, CR with incomplete hematologic recovery; ELN, European LeukemiaNet; Ven, venetoclax.</p>
Links
Where it is published
- DOI doi.org/10.1371/journal.pone.0357898.g002 ↗
DOI / persistent id · from rdr ucl ac uk
Catalogue records · 1
- OAI-PMH record api.figshare.com/v2/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Af… ↗
metadata API · from rdr ucl ac uk
Topics
- From keywords
- Cancer · Earth & Environmental Science · Genetics · Life Sciences · Medicine & Health · Plant biology
Provenance · 1 source records, 11 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| UCL Research Data Repository | oai:figshare.com:article/34050063 | 9 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| concepts[disease].local:disease:cancer | mapping · rdr ucl ac uk | vocabulary-mapper@1.0.0 | keywords['Cancer'] |
| concepts[field].anzsrc:group:3105 | mapping · rdr ucl ac uk | vocabulary-mapper@1.0.0 | keywords['Genetics'] |
| concepts[field].anzsrc:group:3108 | mapping · rdr ucl ac uk | vocabulary-mapper@1.0.0 | keywords['Plant Biology'] |
| concepts[field].local:field:earth-environmental | mapping · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| concepts[field].local:field:life-sciences | mapping · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| concepts[field].local:field:medicine-health | mapping · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| description | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | /metadata/dc/description |
| license | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | /metadata/dc/rights |
| publication_date | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | |
| title | source · rdr ucl ac uk | connector:rdr_ucl_ac_uk@1.0.0 | /metadata/dc/title |